CJC-1295 references you can open and read
The list covers human and animal work, the stopped trial, the FDA review, and the rule for tested sports.
The list below shows where each fact came from
The drug company ConjuChem created CJC-1295 to extend a brief hormone message. These reports show what followed from that work and where the testing stopped.
A bracketed number on another page leads to one item below. Opening that link lets you read the original report for yourself.
Medical journals let you see what happened to human volunteers, mice, or rats. ClinicalTrials.gov is the government list that confirms a later human trial ended early.
FDA papers explain why the agency opposed pharmacy mixing. The world sports authority gives the ban that applies to tested athletes.
Reports connect a patient's death with the stopped DAC program. The public record does not name the compound as the cause, nor does it settle the death's cause.
No honest answer can fill in that missing cause. The full reference list gives you the public reports that are available.
For an easier account of the results, return to the human study findings. The bracket numbers there bring you back to the matching source here.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
- Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. ↗
- Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. ↗
- Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗
- ConjuChem Inc. A study to evaluate CJC-1295 in HIV patients with visceral obesity (Phase 2; discontinued). ClinicalTrials.gov identifier NCT00267527. 2006. ↗
- Modified GRF (1-29) - chemical and pharmacological description (tetrasubstituted, no-DAC GHRH(1-29); short-acting). Encyclopedic reference. 2024. ↗
- Pharmacokinetics of growth hormone releasing factor [GRF(1-29)NH2] in normal men (short native half-life of synthetic GRF(1-29)). 1986. ↗
- PEGylation of growth hormone-releasing hormone (GRF) analogues (alternative half-life-extension strategy). Adv Drug Deliv Rev. 2003. ↗
- Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced GH secretion. Endocrinology. 2002. ↗
- Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. ↗
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) briefing document on growth hormone secretagogues including CJC-1295 (immunogenicity and other safety concerns; not recommended for the 503A bulks list). FDA Advisory Committee Briefing Materials. 2024. ↗
- Renehan AG, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353. (IGF-1/cancer epidemiology context.) ↗
- World Anti-Doping Agency. The Prohibited List - Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics (GHRH analogs including CJC-1295 prohibited at all times). WADA International Standard. 2025. ↗
- Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. ↗
- (2026 peptide therapy safety review). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal conditions. Sports Med. 2026. ↗
- (GH sodium-retention study). GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron. J Clin Endocrinol Metab. 2002. ↗
- (GHRH analog pulsatility/insulin study). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity. J Clin Endocrinol Metab. 2011. ↗